Biocon share price rose 4.5% following US FDA clearance for its Malaysian insulin facility, resolving a regulatory bottleneck ...
Elon Musk said a third person has received an implant from his brain-computer interface company Neuralink, one of many groups ...
Biocon’s shares surged over 7% on January 14, 2025, after HSBC upgraded its rating to ’Buy’ with a target price of ₹430, ...
HSBC expects an operational turnaround for Biocon, driven by major biosimilar launches and a rebound in generics sales. The ...
Brokerages have turned bullish over Biocon's growth prospects after the US FDA clearance of the drugmaker's Malaysia unit ...